Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy

Lee, So Yun; Kang, Moon Sung; Jeong, Woo Yeup; Han, Dong‐Wook; Kim, Ki Su

doi:10.3390/cancers12040940

Cited by 94 publications

(59 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A close association was found between HA receptor expression and malignant tumor progression. HA receptors (especially CD44, hyaluronan-mediated motility receptor RHAMM, lymphatic vessel endothelial hyaluronic acid receptor 1 LYVE1) are activated in cancer cells to promote cell infiltration and tumor malignancy ( Lokeshwar et al, 2014 ; Lee et al, 2020 ). HA promotes the uptake of nanoparticles by binding to these receptors ( Chiesa et al, 2018 ; Rho et al, 2018 ).…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors

et al. 2021

View full text Add to dashboard Cite

Advances in nanotechnology have favored the development of novel colloidal formulations able to modulate the pharmacological and biopharmaceutical properties of drugs. The peculiar physico-chemical and technological properties of nanomaterial-based therapeutics have allowed for several successful applications in the treatment of cancer. The size, shape, charge and patterning of nanoscale therapeutic molecules are parameters that need to be investigated and modulated in order to promote and optimize cell and tissue interaction. In this review, the use of polymeric nanoparticles as drug delivery systems of anticancer compounds, their physico-chemical properties and their ability to be efficiently localized in specific tumor tissues have been described. The nanoencapsulation of antitumor active compounds in polymeric systems is a promising approach to improve the efficacy of various tumor treatments.

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…So far HA has been widely implemented as a favorable biopolymer for producing advanced clinical cancer therapies in various forms such as nanoparticles, micelles, liposomes, and hydrogels, combined with other materials [116]. However, as can be seen from this section, a fraction of such studies reported sustained drug release data.…”

Section: Hyaluronic Acid and Cancer Targeting Drugsmentioning

confidence: 99%

Hyaluronic Acid and Controlled Release: A Review

2020

View full text Add to dashboard Cite

Hyaluronic acid (HA) also known as hyaluronan, is a natural polysaccharide—an anionic, non-sulfated glycosaminoglycan—commonly found in our bodies. It occurs in the highest concentrations in the eyes and joints. Today HA is used during certain eye surgeries and in the treatment of dry eye disease. It is a remarkable natural lubricant that can be injected into the knee for patients with knee osteoarthritis. HA has also excellent gelling properties due to its capability to bind water very quickly. As such, it is one the most attractive controlled drug release matrices and as such, it is frequently used in various biomedical applications. Due to its reactivity, HA can be cross-linked or conjugated with assorted bio-macromolecules and it can effectively encapsulate several different types of drugs, even at nanoscale. Moreover, the physiological significance of the interactions between HA and its main membrane receptor, CD44 (a cell-surface glycoprotein that modulates cell–cell interactions, cell adhesion and migration), in pathological processes, e.g., cancer, is well recognized and this has resulted in an extensive amount of studies on cancer drug delivery and tumor targeting. HA acts as a therapeutic but also as a tunable matrix for drug release. Thus, this review focuses on controlled or sustained drug release systems assembled from HA and its derivatives. More specifically, recent advances in controlled release of proteins, antiseptics, antibiotics and cancer targeting drugs from HA and its derivatives were reviewed. It was shown that controlled release from HA has many benefits such as optimum drug concentration maintenance, enhanced therapeutic effects, improved efficiency of treatment with less drug, very low or insignificant toxicity and prolonged in vivo release rates.

show abstract

“…Several glycoconjugates, such as 99mTc-labeled deoxyglucose derivates and glucosamine functionalized with multiwalled carbon nanotubes, have been employed as diagnostic agents for heart and brain cancer and showed superior accuracy over current diagnostic methods (101,102). However, in recent years, theragnostic systems, such as silica and hyaluronic acid-based NPs that can be used to image cancer cells and at the same time can suppress tumor growth, have been designed by improving the solubility of hydrophobic drugs and glycosylation-mediated drugs and the tumor cell targeting efficiency, with minimum toxicity (103)(104)(105).…”

Section: G-nps Used In Theragnosticsmentioning

confidence: 99%

Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery

Torres-Pérez

Pedraza-Escalona

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Nanoparticles (NPs) are novel platforms that can carry both cancer-targeting molecules and drugs to avoid severe side effects due to nonspecific drug delivery in standard chemotherapy treatments. Cancer cells are characterized by abnormal membranes, metabolic changes, the presence of lectin receptors, glucose transporters (GLUT) overexpression, and glycosylation of immune receptors of programmed death on cell surfaces. These characteristics have led to the development of several strategies for cancer therapy, including a large number of carbohydrate-modified NPs, which have become desirable for use in cell-selective drug delivery systems because they increase nanoparticle-cell interactions and uptake of carried drugs. Currently, the potential of NP glycosylation to enhance the safety and efficacy of carried therapeutic antitumor agents has been widely acknowledged, and much information is accumulating in this field. This review seeks to highlight recent advances in NP stabilization, toxicity reduction, and pharmacokinetic improvement and the promising potential of NP glycosylation from the perspective of molecular mechanisms described for drug delivery systems for cancer therapy. From preclinical proof-of-concept to demonstration of therapeutic value in the clinic, the challenges and opportunities presented by glycosylated NPs, with a focus on their applicability in the development of nanodrugs, are discussed in this review.

show abstract

Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy

Cited by 94 publications

References 110 publications

Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors

Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors

Hyaluronic Acid and Controlled Release: A Review

Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery

Contact Info

Product

Resources

About